Skip to main content

Viridian Therapeutics, Inc.

VRDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001590750

In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Viridian Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of VRDN: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders171169−2
Shares94.6M93.2M−1.35M (−1.4%)
Value$1.32B$2.01B+$689.4M (+52.1%)

New holders (16)

Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to VRDN in Q3 2025
InstitutionSharesValue% of portfolio
Silverarc Capital Management, LLC259,509$5.60M0.81%
Balyasny Asset Management LLC202,821$4.38M0.01%
Propel Bio Management, LLC90,000$1.94M1.94%
Simplify Asset Management Inc.50,000$1.08M0.02%
Campbell & CO Investment Adviser LLC26,315$567.9K0.04%
ExodusPoint Capital Management, LP14,413$311.0K0.00%
Legato Capital Management LLC9,796$211.4K0.02%
Caption Management, LLC8,956$193.3K0.01%
Simplex Trading, LLC2,756$59.0K0.00%
Larson Financial Group LLC2,407$51.9K0.00%
Aster Capital Management (DIFC) Ltd1,632$35.2K0.02%
Rockefeller Capital Management L.P.1,020$22.0K0.00%
Quarry LP801$17.3K0.00%
Optiver Holding B.V.576$12.4K0.00%
SRS Capital Advisors, Inc.115$2.48K0.00%
Montag A & Associates Inc12$2590.00%

Sold out (18)

Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.